Dr. Ilya Finkelshteyn, MD

Dr. Finkelshteyn practices at UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health.

Dr. Finkelshteyn's NPI, 1174910707, was assigned on April 21, 2015. Dr. Finkelshteyn holds California license A176673.

Dr. Finkelshteyn's primary practice is UCLA Santa Monica Medical Center, at 1250 16th Street, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 319-4000.

Dr. Finkelshteyn's primary practice is UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health. Dr. Finkelshteyn is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Finkelshteyn to 2 more hospitals, 1 skilled nursing facility and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Finkelshteyn practices, 5 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Finkelshteyn's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dmand AI has Dr. Finkelshteyn's licenses on file in 2 states: California and Illinois.

CMS data shows 793 Medicare services from Dr. Finkelshteyn across 6 procedure codes in 2024, for 249 Medicare patients. Medicare paid $75,863 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 249 Medicare patients who saw Dr. Finkelshteyn in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 3.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Finkelshteyn's median patient age at 72, with 53% women.

In 2024, Dr. Finkelshteyn wrote 222 Medicare Part D claims for 79 patients. 86% of them were for generic drugs. CMS names the drug for 40 of them, across 3 drugs with 11 or more claims each, at $1,480 in total drug cost. In 2023, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Finkelshteyn for performance year 2024, reported as part of a group. Dr. Finkelshteyn accepts Medicare assignment, so Medicare's approved amount is taken as full payment.